Navigation Links
Some patients may not need insulin for long-term control of type 2 diabetes
Date:6/15/2008

Some patients with type 2 diabetes can control their disease for years yet avoid insulin injections by using multiple classes of oral diabetic medications, a new study found. The results were presented Sunday, June 15, at The Endocrine Society's 90th Annual Meeting in San Francisco.

Findings from the study contradict common beliefs about non-insulin diabetic medications, said principal investigator Arthur Swislocki, MD, of the Veterans Affairs (VA) Northern California Health Care System in Martinez. Oral diabetes medications help control blood glucose, or sugar, levels in people whose bodies still produce some insulin, as is true for many patients with type 2 diabetes.

"Generally, both patients and physicians believe that long-term use of oral diabetic medications is not possible because these drugs lose their effectiveness over time as the patient's pancreas fails," Swislocki said. "Our data suggest that some patients can remain in good glucose control for years using non-insulin, oral diabetic agents."

The study result is good news for people who need medical therapy for type 2 diabetes, according to Swislocki. "They may be able to delay or avoid the use of insulin," he said.

Some patients prefer pills over insulin injections because they are easier to use or because the patient fears needles or getting low blood sugar, as is possible with insulin treatment, he said.

Swislocki and his coworkers studied the VA medical records of 191 veterans (188 men and 3 women) with type 2 diabetes who received treatment beginning in 1992 and received follow-up for 15 consecutive years. Of these patients, 96 began treatment solely with oral drugs. The researchers found that 55 percent of the patients (53 of 96) who started treatment with oral diabetic agents were able to continue using them 15 years later and achieve good blood sugar control. A measure of long-term blood sugar controlhemoglobin A1cimproved from an average of nearly 8 percent to about 7 percent 15 years later in this group.

Of the 96 patients, 45 percent eventually switched to insulin, either alone or in combination with oral drugs. At the beginning of the study, the duration of diabetes was similar between these patients and those who remained on an oral drug regimen. However, the group of patients who stayed on oral medications throughout the study had a lower beginning A1c and were less obese than patients in the other group, the authors reported. They also were more likely to be white. Past studies show minorities have poorer blood sugar control than do whites.

Swislocki said the long-term effectiveness of oral diabetic medications seen in their study may reflect the wider range of oral drugs now available for treating type 2 diabetes, compared with 15 years ago. Therefore, if one class of drugs became less effective, other classes could be added in combination.

The study, however, did not specifically address whether or not oral diabetic drugs lose their effectiveness over a long time, according to Swislocki. Rather, it mainly tracked the prescribing practices of VA primary care providers. "Deductions about drug effectiveness need to be made cautiously," he said.


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Nurses, Doctors, Patients to Protest Health Insurers at National Day of Action - June 19th
2. Joint distraction promotes structural repair in patients with severe knee osteoarthritis
3. 30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
4. Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
5. Serum sodium predicts mortality 10 times higher in PAH patients
6. Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients
7. Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster
8. Research shows patients must re-learn going from sitting to standing after total knee replacement
9. New self-management program offers significant benefits for arthritis patients with chronic pain
10. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
11. Biogen Idecs baminercept alfa shows promise in patients with rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics ... at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, 2017. , ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... the first time support an aid project with the donation of cochlear implants. ... the gift of hearing and thus a fair chance of leading an independent ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... dental problems ranging from gum disease to enamel erosion, and those dental problems ... Massachusetts Department of Public Health, many pregnant women are failing to get the ...
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), ... lurk in the corners and commit the crime of stalking, a very real danger to ... an often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. ...
(Date:1/17/2017)... ... 2017 , ... Gym Source, America’s leading retailer of premium residential and commercial ... in Miami, FL. , “We are elated to be opening this new showroom,” explains ... designed to give clients a seamless and motivating shopping experience.” , Every fitness journey ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... January 17, 2017 Management to Discuss ... Ltd.   KIT-302 Development On Track For An ... in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an ... Monday, January 23 rd at 8:30am Eastern Time to discuss the recent ...
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... patient has been enrolled in a Phase 3 clinical ... best supportive care (BSC) in the prevention of hepatic ... hematopoietic stem cell transplant (HSCT) who are at high ... The defibrotide clinical trial will be conducted across approximately ...
(Date:1/17/2017)... 2017  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, plans to announce ... 2016 after the market closes on Wednesday, February 1, ... p.m. ET that day to discuss those results. ... 407-8037 or (201) 689-8037.  For 72 hours following the ...
Breaking Medicine Technology: